Saturday, Sep 26, 2020 | Last Update : 01:45 AM IST

185th Day Of Lockdown

Maharashtra128396397321434345 Andhra Pradesh6543855794745558 Tamil Nadu5636915082109076 Karnataka5485574446588331 Uttar Pradesh3742773076115366 Delhi2606232243755123 West Bengal2378692080424606 Odisha196888161044805 Telangana1816271501601080 Bihar174266159700878 Assam165582135141608 Kerala15445898720614 Gujarat1289491093113382 Rajasthan1227201023301352 Haryana118554984101177 Madhya Pradesh115361814752007 Punjab105220814752860 Chhatisgarh9562358833680 Jharkhand7643862945626 Jammu and Kashmir68614480791024 Uttarakhand4440432154501 Goa3055224347360 Puducherry2489519311467 Tripura2378616955245 Himachal Pradesh133869232125 Chandigarh109688342123 Manipur9537736959 Arunachal Pradesh8416607113 Nagaland5730459810 Meghalaya4733252838 Sikkim2447190529 Mizoram158510120
  Life   Health  11 Jun 2017  New drug may benefit blood cancer patients

New drug may benefit blood cancer patients

Published : Jun 11, 2017, 11:29 am IST
Updated : Jun 11, 2017, 11:29 am IST

Here's what researchers discovered.

Representational Image. (Photo: Pixabay)
 Representational Image. (Photo: Pixabay)

Washington: A team of US researchers has found that a drug alone or with combination of chemotherapy may show promising results in treating patients with blood cancer.

The researchers focused on two specific proteins, directly involved in DNA repair, called histone deacetylases (HDAC) 1 and 2. The study, conducted on mice, found that the HDAC1,2 inhibitor or the HDAC1,2/doxorubicin combination, their bone marrow started turning from pale to red, indicating the white blood cells were being replaced with red blood cells.


Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have discovered new science that could provide better therapeutic options for patients. Lead study author Srividya Bhaskara from the University of Utah said that the ALL cancer cells containing the Philadelphia chromosome are addicted to repairing DNA.

Bhaskara noted that when the drug was combined with a low concentration of doxorubicin, it had additional therapeutic benefits and using the combination of drugs, or HDAC1,2 inhibitor alone, is sufficient to decrease the leukemia load. Leukemia is a white blood cell disease where the body produces too many white and not enough red blood cells.


The findings revealed that in mouse models, a 50-70 percent reduction in leukemia was observed with either HDAC1,2 inhibitor alone or when the inhibitor was used with doxorubicin. The team tested the HDAC1,2 inhibitor in patient samples and mice and saw encouraging results, either alone or in combination with a chemotherapy drug called doxorubicin. The drugs broke down the central hub of DNA repair and the HDAC1,2 inhibitor actually reduced different repair protein functions

The findings could possibly lead to future novel drug treatments. "Repairing DNA may sound like a good thing when you're talking about healthy cells," she explains, "This inhibitor can work at multiple steps and at multiple levels of repair without causing major toxicity," says Bhaskara. The study is published in the journal Leukemia.


Tags: drugs, cancer treatment, blood cancer, cancer, leukemia